Sanofi announced today that the U.S. FDA has granted orphan drug designation to rilzabrutinib for the treatment of sickle ...

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease <li /> Fourth orphan drug designation for rilzabrutinib ...

DelveInsight's B-cell Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable ...

Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, Institut für Physikalische und Theoretische Chemie, Universität Bonn, D-53115 Bonn, Germany, and Linac ...

Institute of Experimental Physics, Faculty of Mathematics, Physics and Informatics, University of Gdansk, Wita Stwosza 57, 80-308 Gdansk, Poland ...

Our results indicate that hole doping increases the degree of covalency between the anion (As) p states and cation (Mn) d states in the MnAs4 tetrahedron, a crucial ingredient to promote indirect ...

Rilzabrutinib is an investigational, oral, reversible BTK inhibitor developed using Sanofi's proprietary TAILORED COVALENCY platform. This technology enables selective inhibition of BTK while ...

ESBOC is a cornerstone event in the field of chemical biology, offering a platform for scientific discourse, collaboration, and knowledge exchange that allows early career researchers to mix with ...

The B-cell inhibitor market is undergoing significant transformation, driven by a deepening understanding of B-cell biology and its role in a wide range of immune-mediated and oncological diseases ...